In addition to those genetic studies, pharmacological targeting of MEK5 or ERK5 by using BIX02189 or JWG-071, the respective kinase inhibitors of those proteins56,57, significantly decreased the proliferation of sarcoma cell lines. Here, MAP2K5 is linked to sarcoma.